The previous study also showed that Zoptarelin Doxorubicin is a potential therapeutic option for the treatment of triple negative breast cancer, which exhibits a higher percentage of GnRH receptor-positive tumors (30). Here, GNRHR is linked to triple-negative breast carcinoma.